MedImmune, the R&D department of pharma giant AstraZeneca, has licensed the rights to develop and test cancer-fighting drugs to Yale spin-out Koltan Pharmaceuticals. Spun out of the University’s School of Medicine in 2007, the US-based life sciences firm Koltan intends to develop the drug, which has been designed to target a receptor connected to cancers…
Yale licenses MedImmune
Jul 30, 2013 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024